TABLE 1.
Patient characteristics
| n = 26 | |
|---|---|
| Age (years) | 58.8 (9.8) |
| Female/male (n) | 8/18 |
| HFpEF/HFrEF (n) | 7/19 |
| NYHA II/NYHA III (n) | 23/3 |
| Body mass index (kg/m2) | 31.5 (5.4) |
| Left ventricular ejection fraction (%) | 37.2 (12.1) |
| 6‐min walk test (m) | 391 (70) |
| NT‐proBNP (pg/mL) | 778 (726) |
| Beck Depression Inventory‐II score (points) | 6.1 (3.7) |
| General Self‐Efficacy Scale (points) | 31.6 (5.7) |
| Days elapsed since randomization into the trial | 219 (137) |
| Intervention/follow‐up phase of the trial (n) | 12/14 |
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Data are presented as mean (standard deviation) or n (number of patients).